Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma January 8, 2022checkorphan Learn more about: Angioimmunoblastic T-Cell Lymphoma Related Clinical Trial Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Recruitment InformationAdministrative Informations
